Group One Trading sold all its shares 19945 Bank of New York Mellon sold all its shares 24553 KCG Holding sold all its shares 28739
SNOA (MC $23 M) (Cash $13 M) Shares Out: 4.3 M /Undiscovered Stock/ Lots of Marketed Products some of them are in early launch phase plus additional Product launches expected within 6 months / Profitable in 2018 = 1000%+ UPSIDE POTENTIAL..GLTA
Sonoma Pharma (Nasdaq: SNOA)
Market Cap: 22.1 Million Cash: $12.6 Million Price: $5.15
Driving to commercial EBITDAS breakeven, without dilution
Grow current product portfolio with all sales people
•Alevicyn HydroGel, Dermal Spray & Spray Gel for atopic dermatitis & dermal procedures •Celacyn for scar treatment •Mondoxyne for severe acne –launched late 2015 •Ceramax for skin repair in atopic dermatitis–launched in April 2016 •SebuDerm for seborrhea dermatitis –launched in November 2016
Launch 3 New Products –our product pipeline –one every other quarter
•Launching Loyon–Fall 2017 •Ceramax in foam and gel forms –Q4 2017 & Q1 2018
Launch and Grow New and Current Products: During fiscal year 2017, we launched four new dermatology products, including SebuDerm™, Ceramax™, Lasercyn™ Gel and Lasercyn™ Dermal Spray, bringing us to a total of eight dermatology products for the treatment of atopic and seborrheic dermatitis, scar management, surgical procedures, severe acne and “state of the art” skin repair technology. We also obtained three new FDA clearances, now totaling 16 overall. Our strong intellectual property portfolio consists of 63 issued patents and 33 patent applications pending.
We plan to launch our new FDA approved product Loyon® (a skin descaler currently marketed in Europe) in the upcoming months and have a strong product pipeline of several product line improvements, including a line extension of Ceramax™. All in all, we believe this could possibly be our best product line of new FDA approved dermatology and skincare products yet, and we believe our innovation plan will help lead us to profitability.
CLASSIC SEDOR JOHN A receives 10000 shares MIAO GRAHAM G receives 8000 shares PINA KENNETH receives 6000 shares And a small new GOLEMBIEWSKI MICHAEL gets to start 3300 shares. Before receiving shares, let them prove themselves by bringing the finances of PTX in positive!
When under 2?
This company is dead. Manipulation, only to take your money!
Downside risk pretty much eliminated now I would guess, thoughts? Im not sure about you guys but awe-som*sto-cks has provided me with some pretty good trade ideas. I messed up executing some of them but thats on me.
Is PTX undervalued? This sort of setup suggests potential upside... awe-som_sto-cks recently alerted this company i think. google them.